Excitatory Cholinergic and Purinergic Signaling in Bladder Are Equally Susceptible to Botulinum Neurotoxin A Consistent with Co-Release of Transmitters from Efferent Fibers

@article{Lawrence2010ExcitatoryCA,
  title={Excitatory Cholinergic and Purinergic Signaling in Bladder Are Equally Susceptible to Botulinum Neurotoxin A Consistent with Co-Release of Transmitters from Efferent Fibers},
  author={Gary W. Lawrence and Kei Roger Aoki and J Oliver Dolly},
  journal={Journal of Pharmacology and Experimental Therapeutics},
  year={2010},
  volume={334},
  pages={1080 - 1086}
}
Mediators of neuromuscular transmission in rat bladder strips were dissected pharmacologically to examine their susceptibilities to inhibition by botulinum neurotoxins (BoNTs) and elucidate a basis for the clinical effectiveness of BoNT/A in alleviating smooth muscle spasms associated with overactive bladder. BoNT/A, BoNT/C1, or BoNT/E reduced peak and average force of muscle contractions induced by electric field stimulation (EFS) in dose-dependent manners by acting only on neurogenic… 

Figures and Tables from this paper

Functional studies of purinergic and cholinergic interactions in the rat urinary bladder - Characterization of ATP-evoked urothelial release of acetylcholine

Cystitis altered the urothelial signalling, diminishing the purinergic atropinesensitivity, showing this link to be important for healthy bladder signalling and to be affected during cystitis.

Modulation of Purinergic Neuromuscular Transmission by Phorbol Dibutyrate is Independent of Protein Kinase C in Murine Urinary Bladder

The results suggest that PDBu increases the purinergic component of detrusor transmission through increasing neurogenic ATP release via a PKC-independent mechanism.

Botulinum Neurotoxins Serotypes A and B induce paralysis of mouse striated and smooth muscles with different potencies

The established mouse bladder detrusor smooth muscle model is able to discriminate between different botulinum neurotoxin serotypes and could be a useful preclinical tool to explore the pathophysiology of bladder overactivity, as well as the effects of new therapeutic candidates.

β3-adrenoceptor agonists inhibit purinergic receptor-mediated contractions of the murine detrusor.

It is demonstrated that β3-AR agonists, reduce post-junctional purinergic responses in the detrusor via a pathway involving activation of the cAMP effector, EPAC.

BoNT/A in the Urinary Bladder—More to the Story than Silencing of Cholinergic Nerves

The current evidence of BoNT/A’s effect on bladder sensation, potential mechanisms by which it might exert these effects and recent advances in understanding the action ofBoNT in bladder tissue are presented.

Purinergic effects in the rat urinary bladder. Functional studies of cyclophosphamide treatment on afferent and efferent mechanisms

It was concluded that blockade of the P1A1 purinoceptor or inhibition of nitric oxide synthase can alleviate the change in contractile function to CYP-induced bladder inflammation, which was confirmed by the study of several inflammatory findings common in cystitis.

Mechanism of Action of Botulinum Toxin A in Treatment of Functional Urological Disorders

Emerging clinical trials have demonstrated the benefits of BoNT-A treatment in functional urological disorders, including bladder hypersensitivity, overactive bladder, and interstitial cystitis/chronic pelvic pain syndrome.

Knockin mouse models demonstrate differential contributions of synaptotagmin-1 and -2 as receptors for botulinum neurotoxins

Two knockin mutant mouse models containing three designed point-mutations that specifically disrupt BoNT binding in endogenous Syt1 or Syt2 are generated and establish the critical role of protein receptors for the potency and specificity of BoNTs in vivo and demonstrate the differential contributions of SyT1 and SyT2 in two sets of clinically relevant target tissues.
...

References

SHOWING 1-10 OF 50 REFERENCES

PURINERGIC INNERVATION OF THE GUINEA‐PIG URINARY BLADDER

1 A number of criteria for considering adenosine 5′‐triphosphate (ATP) as a neurotransmitter in the guinea‐pig urinary bladder have been examined. In addition, the effect of tachyphylaxis to ATP on

Activation of TRPV1 Mediates Calcitonin Gene-Related Peptide Release, Which Excites Trigeminal Sensory Neurons and Is Attenuated by a Retargeted Botulinum Toxin with Anti-Nociceptive Potential

The basal release of proinflammatory calcitonin gene-related peptide was shown to increase the excitability of trigeminal sensory neurons in brainstem slices via C GRP1 receptors because the effect was negated by an antagonist, CGRP8–37.

Mechanisms of Disease: role of purinergic signaling in the pathophysiology of bladder dysfunction

  • M. Ruggieri
  • Biology, Medicine
    Nature Clinical Practice Urology
  • 2006
Although the 'purinergic nerve hypothesis' proposed by Burnstock in the early 1970s was met with considerable skepticism, it is now accepted that certain neurons use a purine nucleotide or nucleoside

Drug Insight: biological effects of botulinum toxin A in the lower urinary tract

These effects on sensory feedback loops might not only help to explain the mechanism of BTX-A in relieving symptoms of overactive bladder, but also suggest a potential role for BTX -A in the relief of hyperalgesia associated with lower urinary tract disorders.

Physiology and pathophysiology of purinergic neurotransmission.

This review is focused on purinergic neurotransmission, i.e., ATP released from nerves as a transmitter or cotransmitter to act as an extracellular signaling molecule on both pre- and postjunctional

Botulinum neurotoxin A selectively cleaves the synaptic protein SNAP-25

It is demonstrated that BoNT/A acts as a zinc-dependent protease that selectively cleaves SNAP-25, a second component of the putative fusion complex mediating synaptic vesicle exocytosis is targeted by a clostridial neurotoxin.